Neurocrine Biosciences (NBIX) Short-term Investments (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Short-term Investments of $57.4 million for Q2 2026, down 91.93% year-over-year from $711.6 million in Q2 2025, and down 94.53% on a QoQ basis from $1.0 billion in Q1 2026.
Neurocrine Biosciences (NBIX) Short-term Investments (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Short-term Investments for 17 years, with the latest figure at $57.4 million in Q2 2026.
- Short-term Investments for Q2 2026 came in at $57.4 million, down 91.93% year-over-year; the trailing twelve-month figure through Jun 2026 was $57.4 million (down 91.93% YoY), and the FY2025 annual result was $767.4 million, down 8.98% from the prior year.
- Short-term Investments declined to $57.4 million in Q2 2026, from $1.0 billion in the prior quarter.
- Over five years, Short-term Investments peaked at $1.0 billion in Q1 2026 and troughed at $57.4 million in Q2 2026.
- A 5-year average of $718.2 million and a median of $777.6 million in 2023 frame the typical range for Short-term Investments.
- The widest annual swing landed in 2023, when Short-term Investments surged 100.35%; it then plunged 91.93% in 2026.
- A 5-year view of Short-term Investments shows it stood at $726.4 million in 2022, then advanced by 7.45% to $780.5 million in 2023, then grew by 8.02% to $843.1 million in 2024, then dropped by 8.98% to $767.4 million in 2025, then sank by 92.52% to $57.4 million in 2026.
- Per Business Quant data, the three most recent Short-term Investments figures were $57.4 million in Q2 2026, $1.0 billion in Q1 2026, and $767.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 57.40 Mn |
| Mar 31, 2026 | 1.05 Bn |
| Dec 31, 2025 | 767.40 Mn |
| Sep 30, 2025 | 774.60 Mn |
| Jun 30, 2025 | 711.60 Mn |
| Mar 31, 2025 | 749.40 Mn |
| Dec 31, 2024 | 843.10 Mn |
| Sep 30, 2024 | 878.90 Mn |
| Jun 30, 2024 | 899.20 Mn |
| Mar 31, 2024 | 814.30 Mn |
| Dec 31, 2023 | 780.50 Mn |
| Sep 30, 2023 | 801.40 Mn |
| Jun 30, 2023 | 816.50 Mn |
| Mar 31, 2023 | 790.80 Mn |
| Dec 31, 2022 | 726.40 Mn |
| Sep 30, 2022 | 587.20 Mn |
| Jun 30, 2022 | 485.00 Mn |
| Mar 31, 2022 | 394.70 Mn |
| Dec 31, 2021 | 370.50 Mn |
| Sep 30, 2021 | 454.80 Mn |